{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:02:12Z","timestamp":1790283732569,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020624","name":"NIHR Nottingham Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:33:55Z","timestamp":1782214435000},"page":"851-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0296-8210","authenticated-orcid":false,"given":"Jordan","family":"Busby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0914-0416","authenticated-orcid":false,"given":"Tricia M","family":"McKeever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W","family":"Fogarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-2563","authenticated-orcid":false,"given":"Helen L","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.06.003_bib0001","unstructured":"Cystic Fibrosis Trust. UK Cystic Fibrosis Registry 2023 Annual Data Report [Online]. London; 2024. Available from: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2024-11\/CFT_2023_Annual_Data_Report_Oct2024%201.pdf [Accessed 16th June 2026]."},{"key":"10.1016\/j.jcf.2026.06.003_bib0002","unstructured":"James Lind Alliance. Cystic Fibrosis Research Priorities Refresh [Online]. 2022. Available from: https:\/\/www.jla.nihr.ac.uk\/priority-setting-partnerships\/cystic-fibrosis-refresh#tab-cystic-fibrosis-refresh-top-10-priorities [Accessed 16th June 2026]."},{"key":"10.1016\/j.jcf.2026.06.003_bib0003","unstructured":"James Lind Alliance. Cystic Fibrosis Top 10 priorities [Online]. 2017. Available from: https:\/\/www.jla.nihr.ac.uk\/priority-setting-partnerships\/cystic-fibrosis#tab-top-10-priorities [Accessed 16th June 2026]."},{"issue":"4","key":"10.1016\/j.jcf.2026.06.003_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"Supplement 2","key":"10.1016\/j.jcf.2026.06.003_bib0005","article-title":"126 Registry-based RCT to assess change in respiratory function for people with cystic fibrosis established on elexacaftor\/tezacaftor\/ivacaftor after withdrawal of nebulised mucoactive therapies: CF STORM","volume":"24","author":"Davies","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.06.003_bib0006","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","article-title":"Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?","volume":"21","author":"Granger","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.003_bib0007","unstructured":"Cystic Fibrosis Trust. Life-saving drugs campaign timeline [Online]. London; 2025. Available from: https:\/\/www.cysticfibrosis.org.uk\/the-work-we-do\/campaigning-hard\/life-saving-drugs\/campaign-timeline [Accessed 16th June 2026]."},{"key":"10.1016\/j.jcf.2026.06.003_bib0008","unstructured":"Yousaf S., Bonsall A. UK Townsend Deprivation scores from 2011 census data [Online]. UK Data Service: London; 2017. Available from: https:\/\/statistics.ukdataservice.ac.uk\/dataset\/2011-uk-townsend-deprivation-scores\/resource\/194aa538-50dc-4dbc-8ce5-a74d3a2d7c02 [Accessed 16th June 2026]."},{"issue":"3","key":"10.1016\/j.jcf.2026.06.003_bib0009","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2025.11.016","article-title":"Elexacaftor\/tezacaftor\/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis","volume":"25","author":"Sagel","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.003_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2023.05.001","article-title":"Use of cystic fibrosis inhaled medication before and after elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"23","author":"Manika","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.003_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12931-024-03089-2","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis","volume":"26","author":"Gramegna","year":"2025","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.003_bib0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jcf.2024.11.004","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: danish nationwide register study","volume":"24","author":"R\u00e5ket","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.06.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2026.06.003_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2021.08.023","article-title":"Telehealth after the pandemic: will the inverse care law apply? (Commentary)","volume":"20","author":"Calthorpe","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.06.003_bib0015","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcf.2025.08.019","article-title":"Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor\/tezacaftor\/ivacaftor treatment: real-world data from the European cystic fibrosis society patient registry","volume":"24","author":"Pollak","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.003_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.06.003_bib0017","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1513\/AnnalsATS.201801-012OC","article-title":"Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens","volume":"15","author":"Cogen","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.06.003_bib0018","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jcf.2026.06.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108594","article-title":"Improving patient engagement in clinical trials: launching the BOAT trial with key stakeholders","volume":"251","author":"Upadhyay","year":"2026","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2026.06.003_bib0020","unstructured":"Diabetes UK. Number of people living with diabetes in the UK tops 5 million for the first time [Online]. London; 2023. Available from. https:\/\/www.diabetes.org.uk\/about-us\/news-and-views\/number-people-living-diabetes-uk-tops-5-million-first-time [Accessed 16th June 2026]."},{"issue":"7","key":"10.1016\/j.jcf.2026.06.003_bib0021","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/dc25-0044","article-title":"Trends in Cystic Fibrosis\u2013Related diabetes epidemiology between 2003 and 2018 from the U.S. Cystic Fibrosis Foundation patient registry","volume":"48","author":"Kohler","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jcf.2026.06.003_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jcf.2026.06.003_bib0023","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"18","key":"10.1016\/j.jcf.2026.06.003_bib0024","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/nu16183103","article-title":"Is obesity a problem in new Cystic fibrosis treatments?","volume":"16","author":"Sol\u00eds-Garc\u00eda","year":"2024","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.003_bib0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcf.2021.07.003","article-title":"Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation","volume":"21","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.06.003_bib0026","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S2213-2600(13)70002-X","article-title":"The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study","volume":"1","author":"Taylor-Robinson","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.06.003_bib0027","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s12061-024-09583-w","article-title":"50-year deprivation trajectories: local area change in England and Wales, 1971\u20132021","volume":"17","author":"Norman","year":"2024","journal-title":"Appl Spat Anal Policy"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:37:23Z","timestamp":1790282243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016449"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}